Cebix is a biopharmaceutical company focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of diabetic complications, initially peripheral neuropathy in patients with type 1 diabetes.
Carbylan was founded in 2005 to develop and market medical devices and device/drug combination products based on novel, chemically-engineered polymer systems incorporating hyaluronic acid, a well known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat the pain associated with osteoarthritis. Carbylan biopolymers are biocompatible, non-immunogenic and, when combined with pharmaceutical agents, are designed to enable unique, controlled, local drug delivery with sustained therapeutic benefit.
Founded in 2007, Autonomic Technologies (ATI) is pioneering a miniaturized implantable neurostimulation device to provide rapid relief from the debilitating pain and suffering caused by severe headaches. The ATI neurostimulation system is being used in clinical studies for cluster headache and migraine.
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.
Amplimmune develops immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Its founders have identified key immunomodulatory molecules which are the basis for developing a new class of biological treatments that modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients. Amplimmune was acquired by Astrazeneca (AZN) in 2013.
Alvine Pharmaceuticals is dedicated to developing and commercializing therapeutics for the treatment of celiac sprue, a gluten-induced autoimmune disease for which no drug therapy is currently available. Celiac sprue is believed to affect as many as two million people in the U.S. alone, many of whom have suffered the symptoms of the disease but have not yet been diagnosed.